Huntington National Bank Increases Stake in Stryker Co. (NYSE:SYK)

Huntington National Bank grew its position in Stryker Co. (NYSE:SYK - Free Report) by 7.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 267,803 shares of the medical technology company's stock after buying an additional 18,936 shares during the period. Huntington National Bank owned approximately 0.07% of Stryker worth $96,747,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Koshinski Asset Management Inc. purchased a new position in Stryker in the 1st quarter worth about $795,000. Kingsview Wealth Management LLC lifted its position in Stryker by 0.3% during the first quarter. Kingsview Wealth Management LLC now owns 14,166 shares of the medical technology company's stock valued at $5,069,000 after purchasing an additional 47 shares during the period. Lord Abbett & CO. LLC boosted its holdings in Stryker by 5.0% in the first quarter. Lord Abbett & CO. LLC now owns 821 shares of the medical technology company's stock worth $294,000 after purchasing an additional 39 shares during the last quarter. Orion Portfolio Solutions LLC grew its position in Stryker by 10.7% in the 1st quarter. Orion Portfolio Solutions LLC now owns 14,202 shares of the medical technology company's stock worth $5,082,000 after purchasing an additional 1,372 shares during the period. Finally, Great Lakes Retirement Inc. raised its stake in Stryker by 1.9% during the 1st quarter. Great Lakes Retirement Inc. now owns 4,250 shares of the medical technology company's stock valued at $1,521,000 after buying an additional 78 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Stryker stock traded up $1.09 during midday trading on Thursday, reaching $389.43. 750,525 shares of the stock traded hands, compared to its average volume of 1,254,610. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12 month low of $282.35 and a 12 month high of $392.70. The stock's fifty day moving average is $362.94 and its 200-day moving average is $346.72. The stock has a market cap of $148.46 billion, a P/E ratio of 41.62, a PEG ratio of 2.92 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analysts' expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.46 earnings per share. As a group, equities research analysts anticipate that Stryker Co. will post 12.06 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on SYK. Royal Bank of Canada lifted their price objective on Stryker from $386.00 to $400.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Evercore ISI boosted their price target on Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Stifel Nicolaus lowered their price objective on shares of Stryker from $375.00 to $365.00 and set a "buy" rating on the stock in a research note on Wednesday, July 31st. Citigroup boosted their target price on shares of Stryker from $406.00 to $411.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company increased their price target on shares of Stryker from $381.00 to $405.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Stryker has a consensus rating of "Moderate Buy" and an average price target of $393.65.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the sale, the vice president now owns 10,042 shares in the company, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 67,381 shares of company stock valued at $24,825,275 in the last ninety days. Insiders own 5.90% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.